GPG-NH(2 )acts via the metabolite αHGA to target HIV-1 Env to the ER-associated protein degradation pathway

BACKGROUND: The synthetic peptide glycyl-prolyl-glycine amide (GPG-NH(2)) was previously shown to abolish the ability of HIV-1 particles to fuse with the target cells, by reducing the content of the viral envelope glycoprotein (Env) in progeny HIV-1 particles. The loss of Env was found to result from GPG-NH(2 )targeting the Env precursor protein gp160 to the ER-associated protein degradation (ERAD) pathway during its maturation. However, the anti-viral effect of GPG-NH(2 )has been shown to be mediated by its metabolite α-hydroxy-glycineamide (αHGA), which is produced in the presence of fetal bovine serum, but not human serum. In accordance, we wanted to investigate whether the targeting of gp160 to the ERAD pathway by GPG-NH(2 )was attributed to its metabolite αHGA. RESULTS: In the presence of fetal bovine serum, GPG-NH(2), its intermediary metabolite glycine amide (G-NH(2)), and final metabolite αHGA all induced the degradation of gp160 through the ERAD pathway. However, when fetal bovine serum was replaced with human serum only αHGA showed an effect on gp160, and this activity was further shown to be completely independent of serum. This indicated that GPG-NH(2 )acts as a pro-drug, which was supported by the observation that it had to be added earlier to the cell cultures than αHGA to induce the degradation of gp160. Furthermore, the substantial reduction of Env incorporation into HIV-1 particles that occurs during GPG-NH(2 )treatment was also achieved by treating HIV-1 infected cells with αHGA. CONCLUSIONS: The previously observed specificity of GPG-NH(2 )towards gp160 in HIV-1 infected cells, resulting in the production of Env (gp120/gp41) deficient fusion incompetent HIV-1 particles, was most probably due to the action of the GPG-NH(2 )metabolite αHGA.